Quantifying and documenting prior beliefs in clinical trials

Collecting and documenting subjective prior beliefs from knowledgeable clinicians about the potential results of a clinical trial has many advantages. Two large trials of prophylactic treatments in an HIV‐positive population are used as examples. The trials recruited patients of primary care physicians and compared treatments which were in use in clinical practice. Opinions about these trials were elicited from 58 practising HIV clinicians. It is shown how the documented opinions can be used to augment the monitoring process; the prior opinions are updated with interim data using approximate Bayesian methods to give posterior opinions incorporating interim results. These posterior opinions can be used by the monitoring board to anticipate the clinicians' reaction to the results. Eliciting prior beliefs is also ethically important for documenting the nature of the uncertainty or equipoise. Important information is provided for the informed consent process and Institutional Review Board (IRB). Copyright © 2001 John Wiley & Sons, Ltd.

[1]  W. El-Sadr,et al.  A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  W. El-Sadr,et al.  Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. , 1998, The New England journal of medicine.

[3]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[4]  P M Fayers,et al.  Tutorial in biostatistics Bayesian data monitoring in clinical trials. , 1997, Statistics in medicine.

[5]  R. Brettle,et al.  British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals , 1997, The Lancet.

[6]  L. Brammer,et al.  Influenza surveillance--United States, 1992-93 and 1993-94. , 1997, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[7]  Joseph B. Kadane,et al.  Bayesian methods and ethics in a clinical trial design , 1996 .

[8]  L Wasserman,et al.  Robust Bayesian methods for monitoring clinical trials. , 1995, Statistics in medicine.

[9]  L. Joseph,et al.  Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. , 1995, JAMA.

[10]  Donald A. Berry,et al.  Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs , 1994 .

[11]  S. Shapiro,et al.  Ethics and statistics in clinical research: towards a more comprehensive examination , 1994 .

[12]  J P Matts,et al.  Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, The Journal of infectious diseases.

[13]  Bradley P. Carlin,et al.  Bayesian approaches for monitoring clinical trials with an application to toxoplasmic encephalitis prophylaxis , 1993 .

[14]  Thomas A. Louis,et al.  Graphical Elicitation of a Prior Distribution for a Clinical Trial , 1993 .

[15]  M D Hughes,et al.  Reporting Bayesian analyses of clinical trials. , 1993, Statistics in medicine.

[16]  D A Berry,et al.  A case for Bayesianism in clinical trials. , 1993, Statistics in medicine.

[17]  J. Aboulker,et al.  Preliminary analysis of the Concorde trial , 1993, The Lancet.

[18]  H. Waskin,et al.  A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. , 1992, The New England journal of medicine.

[19]  T. Louis.  [Evaluating Therapeutic Interventions: Some Issues and Experiences]: Comment , 1992 .

[20]  Thomas R. Fleming,et al.  Evaluating Therapeutic Interventions: Some Issues and Experiences , 1992 .

[21]  R. Simon,et al.  Bayesian subset analysis. , 1991, Biometrics.

[22]  R. G. Cornell,et al.  Ethics and statistics in randomized clinical trials. , 1991, Statistical science : a review journal of the Institute of Mathematical Statistics.

[23]  Joel B. Greenhouse,et al.  [Investigating Therapies of Potentially Great Benefit: ECMO]: Comment: A Bayesian Perspective , 1989 .

[24]  B. Freedman.  Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.

[25]  J B Kadane,et al.  Progress toward a more ethical method for clinical trials. , 1986, The Journal of medicine and philosophy.

[26]  D. Spiegelhalter,et al.  The Assessment of the Subjective Opinion and its Use in Relation to Stopping Rules for Clinical Trials , 1983 .

[27]  H. Raiffa,et al.  Judgment under uncertainty: A progress report on the training of probability assessors , 1982 .

[28]  T. Beauchamp,et al.  Principles of biomedical ethics , 1991 .

[29]  M. Zelen.  A new design for randomized clinical trials. , 1979, The New England journal of medicine.

[30]  Sounding Board. Reasonableness and randomization in clinical trial: fundamental law and government regulation. , 1979, The New England journal of medicine.

[31]  J. Ware,et al.  Randomized clinical trials. Perspectives on some recent ideas. , 1976, The New England journal of medicine.

[32]  T. Chalmers.  Ethical Aspects of Clinical Trials , 1975 .

[33]  E. Gehan,et al.  Non-randomized controls in cancer clinical trials. , 1974, The New England journal of medicine.

[34]  J. Hartigan.  Linear Bayesian Methods , 1969 .

[35]  Hill Ab,et al.  Medical ethics and controlled trials. , 1963 .